Ascendis Pharma A/S (NASDAQ:ASND) Holdings Lifted by Evolutionary Tree Capital Management LLC

Evolutionary Tree Capital Management LLC boosted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 82.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,862 shares of the biotechnology company’s stock after acquiring an additional 11,223 shares during the period. Ascendis Pharma A/S comprises approximately 3.5% of Evolutionary Tree Capital Management LLC’s portfolio, making the stock its 9th largest position. Evolutionary Tree Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $3,391,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Private Ocean LLC acquired a new stake in shares of Ascendis Pharma A/S in the first quarter valued at approximately $36,000. Quadrant Capital Group LLC boosted its stake in Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC grew its position in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 91 shares during the last quarter. GAMMA Investing LLC grew its position in Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 102 shares during the last quarter. Finally, Barometer Capital Management Inc. acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at $126,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on ASND shares. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. JPMorgan Chase & Co. lowered their target price on Ascendis Pharma A/S from $174.00 to $165.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 4th. The Goldman Sachs Group boosted their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Bank of America increased their price target on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Finally, Citigroup boosted their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $193.77.

Ascendis Pharma A/S Trading Down 1.4 %

ASND stock opened at $151.26 on Friday. The company’s 50-day moving average price is $133.56 and its 200 day moving average price is $136.56. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The company has a market cap of $8.81 billion, a P/E ratio of -15.74 and a beta of 0.63.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.